Tag: FirstLine

Latest News

Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib) Continues to Demonstrate Superiority in the First-Line After Two Years of Follow-Up

Newsemia
CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...
Pharma / Biotech

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

Newsemia
Related Articles A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients. J...
Latest News

LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–LYNPARZA PAOLA-1 Trial Significantly Increased PFS as 1st-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer Source link...
Gastroenterology

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin

Newsemia
Eradicating Helicobacter pylori infection is clinically challenging, notably in cases with penicillin allergy. Cephalosporin could be used in lieu of amoxicillin to eradicate Helicobacter pylori....
Latest News

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

Newsemia
STRASBOURG, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/TG4010?src=hash" target="_blank"gt;#TG4010lt;/agt;–Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces...
Latest News

Simplifying switch to second line ART: Predicted effect of defining failure of first-line efavirenz-based regimens in sub-Saharan Africa by a single viral load > 1000 copies/ml

Newsemia
Shroufi, A; Van Cutsem, G; Cambiano, V; Bansi-Matharu, L; Duncan, K; Murphy, RA; Maman, D; Shroufi, A; Van Cutsem, G; Cambiano, V; Bansi-Matharu, L; Duncan,...
Latest News

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen

Newsemia
Armenia, D; Di Carlo, D; Cozzi-Lepri, A; Calcagno, A; Borghi, V; Gori, C; Bertoli, A; … ICONA Foundation Study Group, ; + view all Armenia,...
Latest News

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Newsemia
KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/Keytruda?src=hash" target="_blank"gt;#Keytrudalt;/agt;–KEYTRUDA in Combination with Inlyta Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy